Heritage Trust Co Purchases Shares of 2,411 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Heritage Trust Co purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,411 shares of the biopharmaceutical company’s stock, valued at approximately $1,717,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in REGN. Kennedy Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 14.5% during the 4th quarter. Kennedy Capital Management LLC now owns 5,156 shares of the biopharmaceutical company’s stock valued at $3,673,000 after purchasing an additional 652 shares during the last quarter. Phoenix Financial Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 19.0% during the fourth quarter. Phoenix Financial Ltd. now owns 2,103 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 336 shares during the period. F M Investments LLC increased its holdings in Regeneron Pharmaceuticals by 8.5% during the 4th quarter. F M Investments LLC now owns 7,003 shares of the biopharmaceutical company’s stock valued at $4,988,000 after purchasing an additional 550 shares during the period. APG Asset Management N.V. raised its holdings in shares of Regeneron Pharmaceuticals by 275.5% during the fourth quarter. APG Asset Management N.V. now owns 81,755 shares of the biopharmaceutical company’s stock valued at $56,240,000 after acquiring an additional 59,984 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.7% in the 4th quarter. Advisory Services Network LLC now owns 4,922 shares of the biopharmaceutical company’s stock worth $3,506,000 after purchasing an additional 129 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $546.39 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $662.80 and a 200-day moving average price of $758.54. The firm has a market capitalization of $59.73 billion, a PE ratio of 14.27, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on REGN shares. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen dropped their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.